Repurposing the β(3)-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial

IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β(3)-adrenergic receptors (β3ARs) may represen...

Descripción completa

Detalles Bibliográficos
Autores principales: Balligand, Jean-Luc, Brito, Dulce, Brosteanu, Oana, Casadei, Barbara, Depoix, Christophe, Edelmann, Frank, Ferreira, Vanessa, Filippatos, Gerasimos, Gerber, Bernhard, Gruson, Damien, Hasenclever, Dirk, Hellenkamp, Kristian, Ikonomidis, Ignatios, Krakowiak, Bartosz, Lhommel, Renaud, Mahmod, Masliza, Neubauer, Stefan, Persu, Alexandre, Piechnik, Stefan, Pieske, Burkert, Pieske-Kraigher, Elisabeth, Pinto, Fausto, Ponikowski, Piotr, Senni, Michele, Trochu, Jean-Noël, Van Overstraeten, Nancy, Wachter, Rolf, Pouleur, Anne-Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512168/
https://www.ncbi.nlm.nih.gov/pubmed/37728907
http://dx.doi.org/10.1001/jamacardio.2023.3003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512168/
https://www.ncbi.nlm.nih.gov/pubmed/37728907
http://dx.doi.org/10.1001/jamacardio.2023.3003

Ejemplares similares